TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma.

Bertrand F, Montfort A, Marcheteau E, Imbert C, Gilhodes J, Filleron T, Rochaix P, Andrieu-Abadie N, Levade T, Meyer N, Colacios C, Ségui B. · 2017

Read TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma. by Bertrand F, Montfort A, Marcheteau E, Imbert C, Gilhodes J, Filleron T, Rochaix P, Andrieu-Abadie N, Levade T, Meyer N, Colacios C, Ségui B. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5741628.txt.

Introduction

Bertrand and co-authors test whether blocking TNF helps anti-PD-1 drugs work in melanoma. Anti-PD-1 antibodies changed care for this skin cancer, yet many patients gain nothing. Others relapse after a first response. TNF, an immune signal, may play a part in that failure.

In mouse melanoma, TNF blockade paired with anti-PD-1 to strong effect. Blocking TNF kept tumor fighting T cells alive. It also held down PD-L1 and TIM-3, two further brakes on immunity. Human melanoma samples show TNF rising with both brakes. The team proposes paired anti-PD-1 and anti-TNF care for patients.

Catalog record

CREATORBertrand F, Montfort A, Marcheteau E, Imbert C, Gilhodes J, Filleron T, Rochaix P, Andrieu-Abadie N, Levade T, Meyer N, Colacios C, Ségui B.
YEAR2017
COLLECTIONPAPERS
FORMATTXT
FILE SIZE53 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5741628

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma By Florie Bertrand, Anne Montfort, Elie Marcheteau, Caroline Imbert, Julia Gilhodes, Thomas Filleron, Philippe Rochaix, Nathalie Andrieu-Abadie, Thierry Levade, Nicolas Meyer, Céline Colacios, Bruno Ségui Published in: Nature Communications DOI: 10.1038/s41467-017-02358-7 ABSTRACT Antibodies against programmed cell death-1 (PD-1) have considerably changed the treatment for melanoma. However, many patients do not display therapeutic response or eventually relapse. Moreover, patients treated with anti-PD-1 develop immune-related adverse events that can be cured with anti-tumor necrosis factor α (TNF) antibodies. Whether anti-TNF antibodies affect the anti-cancer immune response remains unknown. Our recent work has highlighted that TNFR1-dependent TNF signalling impairs the accumulation of CD8+ tumor-infiltrating T lymphocytes (CD8+ TILs) in mouse melanoma. Herein, our results indicate that TNF or TNFR1 blockade synergizes with anti-PD-1 on anti-cancer immune responses towards solid cancers. Mechanistically, TNF blockade prevents anti-PD-1-induced TIL cell death as well as PD-L1 and TIM-3 expression. TNF expression positively correlates with expression of PD-L1 and TIM-3 in human melanoma specimens. This study provides a strong rationale to develop a combination therapy based on the use of anti-PD-1 and anti-TNF in cancer patients. INTRODUCTION Tumor necrosis factor α (TNF) plays a dual role in oncoimmunology1–3, either acting as an anti-cancer factor4,5, or behaving as an immunosuppressive cytokine6–11. Whereas TNF was first identified as a cytotoxic soluble factor4, mounting evidence indicates that TNF facilitates the accumulation and/or biological activity of regulatory T lymphocytes (Tregs)12, regulatory B lymphocytes (Bregs)8 as well as myeloid-derived suppressor cells (MDSC)9, which are key negative modulators of the immune response. Moreover, TNF triggers activation-induced cell death (AICD) of CD8+ T cells13 and impairs the tumor infiltration by CD8+ T lymphocytes1,2,14. CD4+ tumor-infiltrating lymphocytes (TILs) in melanoma produce TNF, which inhibits cytotoxic CD8+ T-cell responses15. In an adoptive CD8+ T-cell transfer protocol, TNF elicited melanoma dedifferentiation, promoting immune escape and melanoma relapse16. More recently, TNF has been shown to enhance the expression of programmed cell death ligand 1 (PD-L1) in cancer cells17, including melanoma15, triggering immunosuppression. Emerging immunotherapies that target immune checkpoints, like anti-PD-1 (programmed cell death-1), have radically changed our strategy to fight melanoma18. However, 60–67% of patients do not respond to anti-PD-119,20, and a significant proportion of responders experience tumor relapse within two years after treatment induction19–21. One of the documented cause of this relapse was shown to be the expression of secondary immune checkpoints such as T-cell Immunoglobulin and Mucin domain-containing protein 3 (TIM-3)22. Anti-PD-1 treatment is associated with increased TNF gene expression in melanoma samples from metastatic melanoma patients23. In this context, the contribution of TNF to the anti-melanoma immune response is unknown. In addition, responders develop severe immune-related adverse events (irAEs) with a frequency close to 12%19,20. Whereas anti-TNF antibodies are used to cure irAEs associated with immunotherapies (such as anti-CTLA-4, anti-PD-1 or a combination of both)24, whether TNF blockade affects the anti-melanoma immune response triggered by immunotherapies remains to be determined. Herein, we have evaluated the consequences of blocking the TNFR1-dependent TNF signalling on anti-PD-1 efficacy in experimental cancer. We provide evidence for the first time that TNF impairs the response to anti-PD-1 not only in mouse melanoma but also in two other experimental cancers (i.e., lung and breast cancer). Mechanistically, TNF induced upon anti-PD-1 treatment triggers (i) the expression of both PD-L1 and TIM-3 on CD4+ and CD8+ TILs and (ii) AICD in CD8+ TILs, which co-express PD-1 and TIM-3. Consequently, TNF blockade/deficiency prevents PD-L1 and TIM-3 expression as well as AICD in CD8+ TILs, overcoming the resistance to anti-PD-1 in experimental melanoma. RESULTS TNF/TNFR1 deficiency potentiates anti-PD-1 treatment efficacy We investigated the impact of TNF deficiency on the therapeutic effect of anti-PD-1 on melanoma development. To this end, wild-type (WT) and TNF-deficient mice were bilaterally injected with 3.105 melanoma cells. When tumors became detectable (i.e., palpable, at day 6), mice received the first out of three injections of anti-PD-1 blocking antibody or isotype control. In agreement with previous observations14, B16K1 tumor growth (Figs. 1a and b) and animal death (Fig. 1c) were significantly delayed in TNF-deficient mice as compared to their WT counterparts. In WT animals, anti-PD-1 injections significantly delayed the B16K1 tumor growth. However, most of the tumors relapsed and all mice died within 50–60 days post-tumor cell injection (Figs. 1a and c). Remarkably, in TNF-deficient mice, anti-PD-1 therapy led to the rejection of 90% of tumors (Figs. 1a and b). Moreover, more than 80% of these mice survived up to 120 days (Fig. 1c). Similar results were obtained when anti-PD-1 was administered to WT and TNF-deficient mice bearing larger tumors (about 25 mm3 at day 6) (Figs. 1d–f). Of interest, all TNFR1-deficient mice (Supplementary Fig. 1) as well as WT mice injected with an anti-TNFR1 blocking antibody (Supplementary Fig. 2) rejected melanoma cells upon anti-PD-1 therapy. Two months after the first B16K1 melanoma cell inoculation, B16K1 melanoma cell re-injection in the surviving TNF- and TNFR1-deficient mice did not compromise overall survival, demonstrating that animals were totally vaccinated towards B16K1 melanoma cells (Fig. 1c and Supplementary Fig. 1c).Fig. 1TNF deficiency enhances anti-PD-1 response in a mouse melanoma model. C57BL/6 wild-type (WT) and TNF-deficient (TNF−/−) mice were intradermally and bilaterally grafted with 3 × 105 (a–c) (n = 11 mice per group) or 1 × 106 (d–f) (n = 6 mice per group). B16K1 melanoma cells prior to intraperitoneal injection of anti-PD-1 antibodies (αPD-1, 10 mg kg−1) or a relevant isotype control (Iso, 10 mg kg−1) at days 6, 10 and 13. a and d Tumor volumes were determined with a calliper. Individual curves are depicted for each tumor. Numbers indicate complete tumor regression out of total tumors. Data are from three independent experiments. b and e Tumor volumes determined at the indicated days for individual tumors are depicted. Bars represent mean values ± s.e.m. (Mann–Whitney U test: *p < 0.05; **p < 0.01; ***p < 0.001). c and f Cumulative survival curves (Logrank test: *p < 0.05; **p < 0.01; ***p < 0.001). At day 60, surviving mice were challenged with a second B16K1 injection as indicated by the arrow; mice did not develop tumors and survived (c) To extend our observations to another cancer model, we tested the effect of anti-PD-1 blocking antibodies in WT, TNF- and TNFR1-deficient mice injected with Lewis lung carcinoma (LLC) cells, which expressed MHC-I at low levels (Supplementary Fig. 3a). Neither TNF nor TNFR1 deficiency impaired LLC growth. Moreover, in WT mice, anti-PD-1 had no effect on tumor growth indicating that LLC were fully resistant to this therapy under our experimental conditions (Supplementary Fig. 3b and c). Of interest, TNF or TNFR1 deficiency partially overcame the resistance of LLC to anti-PD-1 (Supplementary Fig. 3b and c). Thus, synergism of TNF/TNFR1 deficiency and anti-PD-1 is likely not restricted to melanoma but applies to other cancers, such as lung carcinoma, which can benefit from anti-PD-1 according to phase 2 and phase 3 clinical trials25,26. Collectively, our data indicate that the TNFR1-dependent TNF signalling impairs the therapeutic benefit of PD-1 blockade. TNF deficiency reduces TIL cell death upon anti-PD-1 therapy To get insights into the molecular and cellular mechanisms involved in the beneficial effect of TNF blockade in anti-PD-1 therapy, we bilaterally grafted one million B16K1 cells in WT and TNF-deficient mice

Read the complete text